Analysts Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) PT at $12.00

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $12.00.

A number of brokerages have issued reports on SABS. Leerink Partners boosted their price objective on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. Jefferies Financial Group began coverage on shares of SAB Biotherapeutics in a research note on Wednesday, May 20th. They set a “buy” rating and a $11.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Citigroup assumed coverage on shares of SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price target on the stock. Finally, Weiss Ratings downgraded shares of SAB Biotherapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd.

SAB Biotherapeutics Trading Down 0.3%

NASDAQ SABS opened at $3.41 on Friday. SAB Biotherapeutics has a fifty-two week low of $1.85 and a fifty-two week high of $5.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.22 and a current ratio of 9.22. The stock has a 50 day simple moving average of $3.70 and a two-hundred day simple moving average of $3.77. The stock has a market cap of $310.26 million, a P/E ratio of -2.62 and a beta of 0.53.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). On average, analysts forecast that SAB Biotherapeutics will post -1.17 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. purchased a new position in shares of SAB Biotherapeutics in the 1st quarter valued at approximately $29,000. State of Wyoming purchased a new stake in SAB Biotherapeutics in the fourth quarter worth $34,000. ADAR1 Capital Management LLC raised its holdings in SAB Biotherapeutics by 75.6% in the fourth quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after purchasing an additional 11,344 shares in the last quarter. State Street Corp purchased a new position in SAB Biotherapeutics during the fourth quarter valued at $49,000. Finally, Fifth Lane Capital LP purchased a new position in SAB Biotherapeutics during the fourth quarter valued at $56,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.